Pregabalin市场规模、份额和成长分析（按剂型、应用、药物类别、通路、最终用户和地区划分）—2026-2033年产业预测

预计到 2024 年，全球Pregabalin市场规模将达到 19.7 亿美元，到 2025 年将达到 20.5 亿美元，到 2033 年将达到 27.6 亿美元，预测期（2026-2033 年）的复合年增长率为 3.8%。

受神经系统疾病（尤其是癫痫和神经病变疼痛）在成人中日益普遍的影响，Pregabalin市场正经历显着增长。市场相关人员致力于改善低收入和医疗服务不足地区的用药可及性，也促进了这一成长。全球有超过5000万人患有癫痫，由于许多患者预计将透过适当的治疗实现无癫痫发作，因此对Pregabalin的需求仍然强劲。成人，尤其是25至60岁的人群，是该市场的主要消费群体，他们患有神经病变疼痛、纤维肌痛和整体焦虑症等慢性疾病的比例最高。此外，低收入国家治疗资源的匮乏凸显了提高药物可及性的必要性，进一步推动了Pregabalin市场的成长。

全球Pregabalin市场驱动因素

神经病变疼痛和整体焦虑症发病率的不断上升显着推动了全球对Pregabalin的需求。已开发国家和发展中国家的医疗专业人员越来越多地推荐Pregabalin，因为它具有治疗慢性疼痛和缓解焦虑症状的双重疗效。此外，世界各地更新的临床指南已将Pregabalin列为一线治疗药物，扩大了其在神经病学和精神病学领域的应用。Pregabalin日益增长的认可度和适应症范围，使其在旨在改善患者预后的药物治疗中扮演越来越重要的角色。

限制全球Pregabalin市场的因素

由于Pregabalin在许多地区被列为管制药物，其全球市场面临许多挑战，限制了市场成长。对滥用和成瘾风险的担忧促使监管机构实施了严格的处方限制。这些限制阻碍了Pregabalin的普及，尤其是在全科诊所和门诊机构，因为医疗服务提供者可能由于繁琐的文书工作而犹豫是否开立处方。此外，全面的记录和监测要求也可能进一步阻碍一些医疗专业人员向患者提供该药物，从而阻碍整体市场渗透，并限制了可能受益于该治疗的患者获得治疗的机会。

全球Pregabalin市场趋势

全球Pregabalin市场正处于显着成长阶段，这主要得益于市场对有效神经病变疼痛缓解方案日益增长的需求。随着慢性疼痛在老年族群中持续增加，尤其是在北美和欧洲，医疗保健提供者和患者都越来越多地选择Pregabalin来治疗糖尿病神经病变和带状疱疹后遗症神经痛等疾病。这种需求的激增促使製药公司致力于推出特殊剂型和长效製剂，以满足不同患者的需求。尤其关注老年患者群体，凸显了製药业在提高疼痛管理策略的耐受性和依从性方面所做的努力。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 顾客购买行为分析

全球Pregabalin市场规模（依剂型划分）及复合年增长率（2026-2033 年）

• 口服胶囊
• 口服液
• 口服锭剂
• 缓释製剂

全球Pregabalin市场规模（依应用及复合年增长率划分）（2026-2033 年）

• 癫痫
• 神经病变疼痛
• 焦虑症
• 其他的

全球Pregabalin市场规模（依药物类别及复合年增长率划分）（2026-2033 年）

• 纤维肌痛治疗药物
• 抗惊厥药
• 其他的

全球Pregabalin市场规模（依通路划分）及复合年增长率（2026-2033 年）

• 医院药房
• 零售药房
• 网路药房
• 其他的

全球Pregabalin市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 专科诊所
• 居家医疗
• 其他的

全球Pregabalin市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Pfizer Inc.（US）
• GSK plc（UK）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sanofi（France）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Zydus Cadila（India）
• Lupin（India）
• Amneal Pharmaceuticals LLC.（US）
• Cipla Inc.（US）
• Torrent Pharmaceuticals Ltd.（India）
• Aurobindo Pharma Limited（India）
• Glenmark Pharmaceuticals Limited（India）
• Medley Pharmaceuticals Ltd.（India）
• Genesisbiotec（India）
• Biomax Biotechnics（India）

结论与建议

Global Pregabalin Market size was valued at USD 1.97 Billion in 2024 and is poised to grow from USD 2.05 Billion in 2025 to USD 2.76 Billion by 2033, growing at a CAGR of 3.8% during the forecast period (2026-2033).

The pregabalin market is experiencing significant growth driven by the increasing prevalence of neurological disorders, particularly epilepsy and neuropathic pain among adults. Efforts by market players to enhance access in low-income and underserved regions are also contributing to this expansion. With over 50 million individuals worldwide affected by epilepsy, and a large percentage potentially achieving seizure freedom through proper treatment, the demand for pregabalin remains robust. The adult demographic, particularly those aged 25 to 60, displays the highest incidence of chronic conditions such as neuropathic pain, fibromyalgia, and generalized anxiety disorder, making it the primary consumer segment. Furthermore, significant gaps in treatment availability in low-income countries highlight the need for improved accessibility, thereby further propelling the growth of the pregabalin market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pregabalin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pregabalin Market Segments Analysis

Global Pregabalin Market is segmented by Forms, Application, Drug Class, Distribution Channel, End User and region. Based on Forms, the market is segmented into Oral Capsule, Oral Solution, Oral Tablet and Extended Release. Based on Application, the market is segmented into Epilepsy, Neuropathic Pain, Anxiety Disorder and Others. Based on Drug Class, the market is segmented into Fibromyalgia Agents, Anticonvulsants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pregabalin Market

The growing incidence of neuropathic pain and generalized anxiety disorders is significantly boosting the global demand for pregabalin. Healthcare professionals in both advanced and developing regions are increasingly recommending pregabalin due to its dual therapeutic applications in managing chronic pain and alleviating anxiety symptoms. Furthermore, the inclusion of pregabalin as a first-line treatment option in updated clinical guidelines across various countries is enhancing its utilization in the fields of neurology and psychiatry. This expanding acceptance and application of pregabalin are contributing to its rising prominence in pharmaceutical therapies aimed at improving patient outcomes.

Restraints in the Global Pregabalin Market

The global pregabalin market faces significant challenges due to its classification as a controlled substance in many regions, which restricts its market growth. Concerns over potential abuse and dependency prompt regulatory bodies to enforce stringent prescribing restrictions. These regulations create barriers for adoption, particularly among general care units and outpatient settings, as healthcare providers may hesitate to prescribe pregabalin due to the increased administrative requirements involved. The need for comprehensive record keeping and oversight may further discourage some practitioners from offering it to patients, ultimately hindering its overall penetration in the market and limiting accessibility for those who may benefit from the treatment.

Market Trends of the Global Pregabalin Market

The global pregabalin market is witnessing a notable upward trajectory, driven by heightened demand for effective neuropathic pain relief solutions. As chronic pain disorders, particularly prevalent among the aging population in North America and Europe, continue to rise, healthcare providers and patients alike are increasingly turning to pregabalin for managing conditions like diabetic neuropathy and post-herpetic neuralgia. This surge in demand is prompting pharmaceutical companies to innovate, leading to the introduction of specialized dosage forms and long-acting formulations tailored to meet diverse patient needs. The focus on geriatric patients further emphasizes the industry's commitment to enhancing tolerability and compliance in pain management strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Pregabalin Market Size by Forms & CAGR (2026-2033)

• Market Overview
• Oral Capsule
• Oral Solution
• Oral Tablet
• Extended Release

Global Pregabalin Market Size by Application & CAGR (2026-2033)

• Market Overview
• Epilepsy
• Neuropathic Pain
• Anxiety Disorder
• Others

Global Pregabalin Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Fibromyalgia Agents
• Anticonvulsants
• Others

Global Pregabalin Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Pregabalin Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Pregabalin Market Size & CAGR (2026-2033)

• North America (Forms, Application, Drug Class, Distribution Channel, End User)
  • US
  • Canada
• Europe (Forms, Application, Drug Class, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Forms, Application, Drug Class, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Forms, Application, Drug Class, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Forms, Application, Drug Class, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (U.K.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals LLC. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medley Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genesisbiotec (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomax Biotechnics (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations